Has Dipna Pharmachem declared dividend?

No Dividend History Available

What is the technical trend for Dipna Pharmachem?

As of June 2, 2025, Dipna Pharmachem's technical trend is mildly bullish, supported by strong weekly indicators and bullish Bollinger Bands, but tempered by mixed monthly signals and a mildly bearish outlook from Dow Theory.

As of 2 June 2025, the technical trend for Dipna Pharmachem has changed from bullish to mildly bullish. The weekly MACD remains bullish, while the monthly MACD is mildly bearish, indicating mixed signals across time frames. The RSI shows no signal on the weekly chart and is bearish on the monthly chart, suggesting weakening momentum. Bollinger Bands are bullish on both weekly and monthly time frames, supporting a positive outlook. Daily moving averages are bullish, reinforcing the mildly bullish stance. However, Dow Theory indicates a mildly bearish trend on the weekly chart, which adds caution. Overall, the current technical stance is mildly bullish, driven by strong weekly indicators but tempered by monthly bearish signals.

Who are the peers of the Dipna Pharmachem?

Dipna Pharmachem's peers include Vasundhara Rasy., Vivo Bio Tech, Godavari Drugs, Concord Drugs, Lasa Supergeneri, Medi Caps, Shelter Pharma, Transchem, and Sandu Pharma. Dipna Pharmachem leads in 1-year returns at 203.59%, significantly outperforming its peers.

Peers: The peers of Dipna Pharmachem are Vasundhara Rasy., Vivo Bio Tech, Godavari Drugs, Concord Drugs, Lasa Supergeneri, Medi Caps, Shelter Pharma, Transchem, and Sandu Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Shelter Pharma, while Average management risk is found at Vasundhara Rasy., Vivo Bio Tech, Godavari Drugs, Medi Caps, and Transchem. Below Average management risk is noted for Concord Drugs, Lasa Supergeneri, Dipna Pharmachem, Sandu Pharma, and the rest. Growth is Excellent for Dipna Pharmachem, Below Average for Vasundhara Rasy., Vivo Bio Tech, Godavari Drugs, Concord Drugs, Lasa Supergeneri, Medi Caps, Transchem, and Sandu Pharma, and Good for Shelter Pharma. Capital Structure is Good for Vasundhara Rasy. and Medi Caps, Average for Lasa Supergeneri, Below Average for Vivo Bio Tech, Godavari Drugs, Concord Drugs, Dipna Pharmachem, Transchem, and Sandu Pharma, and Excellent for Shelter Pharma.<BR><BR>Return Snapshot: Dipna Pharmachem has the highest 1-year return at 203.59%, while Lasa Supergeneri has the lowest at -49.73%. Dipna Pharmachem's return significantly outperforms all peers. Additionally, the six-month return is negative for Lasa Supergeneri, Medi Caps, and Shelter Pharma.

Who are in the management team of Dipna Pharmachem?

As of March 2022, the management team of Dipna Pharmachem includes Keyur Shah (Managing Director), Dipna Shah (Director), Nandish Jani, Chinu Kalal, and Jitendra Parmar (Independent Directors), along with Khushboo Jethaliya and Madhuri Gurwani (Company Secretaries & Compliance Officers).

As of March 2022, the management team of Dipna Pharmachem includes the following individuals:<BR><BR>1. Keyur Shah - Managing Director<BR>2. Dipna Shah - Director<BR>3. Nandish Jani - Independent Director<BR>4. Chinu Kalal - Independent Director<BR>5. Khushboo Jethaliya - Company Secretary & Compliance Officer<BR>6. Jitendra Parmar - Independent Director<BR>7. Madhuri Gurwani - Company Secretary & Compliance Officer<BR><BR>These members play various roles in the governance and management of the company.

What does Dipna Pharmachem do?

Dipna Pharmachem Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, incorporated in 2011 and transitioned to public status in 2022. It currently has no reported sales or profit data, with a market cap of INR 60 Cr.

Overview:<BR>Dipna Pharmachem Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>Dipna Pharmachem Private Limited was incorporated in 2011 and changed its name to Dipna Pharmachem Private Limited in 2012. The company transitioned from Private Limited to Public Limited status and was renamed Dipna Pharmachem Limited on May 25, 2022. There is no recent sales or profit data reported.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: N/A<BR>Market-cap value: INR 60 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 57.00<BR>Industry P/E: 37<BR>Dividend Yield: 0.00%<BR>Debt-Equity: 0.15<BR>Return on Equity: 2.59%<BR>Price-to-Book: 1.60<BR><BR>Contact Details:<BR>Registrar Address: Not available. <BR>Phone: N/A<BR>Email: N/A<BR>Website: N/A

Who are the top shareholders of the Dipna Pharmachem?

The top shareholders of Dipna Pharmachem include promoter Keyur Dipakkumar Shah with 9.97% and public shareholder Teena Kirti Jain with 4.1%. Individual investors hold a significant 71.21% of the shares, with no institutional holdings reported.

The top shareholders of Dipna Pharmachem include Keyur Dipakkumar Shah, who is the promoter with the highest holding at 9.97%. The highest public shareholder is Teena Kirti Jain, holding 4.1%. Additionally, individual investors collectively hold a significant portion of the company, accounting for 71.21% of the shares. There are no institutional holdings from mutual funds or foreign institutional investors.

How big is Dipna Pharmachem?

As of 23rd July, Dipna Pharmachem Ltd has a market capitalization of 59.00 Cr, categorizing it as a Micro Cap company. Financial data for the latest quarterly performance is unavailable, but as of March 2024, Shareholder's Funds are 37.52 Cr and Total Assets are 132.90 Cr.

As of 23rd July, Dipna Pharmachem Ltd has a market capitalization of 59.00 Cr, which categorizes it as a Micro Cap company.<BR><BR>There is no valid financial data available for the latest quarterly performance, including Net Sales and Net Profit for the latest four quarters.<BR><BR>The reporting period for the balance sheet is March 2024, with Shareholder's Funds amounting to 37.52 Cr and Total Assets valued at 132.90 Cr.

When is the next results date for Dipna Pharmachem?

Dipna Pharmachem will announce its results on 26 November 2025.

Dipna Pharmachem will declare its results on 26 November 2025.

Is Dipna Pharmachem overvalued or undervalued?

As of November 21, 2025, Dipna Pharmachem is considered overvalued due to a high PE ratio of 41.87 and low ROE of 2.52%, despite a strong one-year stock return of 150.22%, especially when compared to peers like Sun Pharma and Cipla.

As of 21 November 2025, Dipna Pharmachem's valuation grade has moved from fair to expensive, indicating a shift towards overvaluation. The company is currently considered overvalued based on its high PE ratio of 41.87, an EV to EBIT ratio of 16.69, and a ROE of only 2.52%. In comparison, peers such as Sun Pharma have a PE of 36.98 and an EV to EBITDA of 24.43, while Cipla, which is rated attractive, has a significantly lower PE of 22.45 and an EV to EBITDA of 15.88.<BR><BR>Given these ratios and the peer comparison, Dipna Pharmachem appears to be overvalued in the current market context. Despite a strong one-year stock return of 150.22%, which outperformed the Sensex's 10.47%, the company's financial metrics suggest that its stock price may not be justified at this level.

How has been the historical performance of Dipna Pharmachem?

Dipna Pharmachem has experienced a significant decline in financial performance, with net sales dropping from 727.56 Cr in March 2022 to 124.92 Cr by March 2025, alongside decreasing operating profit and negative cash flow from operations. Despite stable total liabilities, the overall trend indicates ongoing challenges in profitability and sales.

Answer:<BR>The historical performance of Dipna Pharmachem shows significant fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>Dipna Pharmachem's net sales peaked at 727.56 Cr in March 2022 but have since declined to 124.92 Cr by March 2025. The total operating income followed a similar trend, dropping from 727.56 Cr in March 2022 to 124.93 Cr in March 2025. The company's operating profit (PBDIT) also saw a decline from 22.10 Cr in March 2022 to 3.45 Cr in March 2025, while profit before tax remained relatively stable at 1.42 Cr in March 2025 compared to 1.42 Cr in March 2024. Profit after tax showed a slight decrease from 1.09 Cr in March 2024 to 0.97 Cr in March 2025. The company's total liabilities have remained relatively stable, with a slight decrease from 132.90 Cr in March 2024 to 132.38 Cr in March 2025. Cash flow from operating activities has been negative, with -9.00 Cr in March 2025, indicating ongoing challenges in generating cash from operations. Overall, the financial performance of Dipna Pharmachem reflects a downward trend in sales and profitability over the past few years.

Which are the latest news on Dipna Pharmachem?

Why is Dipna Pharmachem falling/rising?

As of 04-Dec, Dipna Pharmachem Ltd's stock price is rising to 15.99, reflecting a short-term upward trend after previous declines. However, it remains below key moving averages and has seen a significant drop in investor participation, indicating potential challenges ahead.

As of 04-Dec, Dipna Pharmachem Ltd's stock price is rising, currently at 15.99, with a change of 0.26 (1.65%) upward. This increase can be attributed to a trend reversal, as the stock has gained after two consecutive days of decline. Additionally, it has outperformed the sector by 1.36% today, indicating a relative strength compared to its peers.<BR><BR>However, it is important to note that despite the current rise, the stock is trading lower than its moving averages across various time frames (5-day, 20-day, 50-day, 100-day, and 200-day), which suggests a longer-term downward trend. Furthermore, there has been a significant drop in investor participation, with the delivery volume on 03 Dec falling by 77.61% compared to the 5-day average, indicating reduced interest from investors.<BR><BR>Overall, while the stock is experiencing a short-term rise, the broader context shows challenges such as lower trading volumes and being below moving averages, which could impact its future performance.